However, many researchers underline the higher diagnostic value of the NMP22 test
than cytology particularly for the T stage and G grade.
A routine cytologic examination and NMP22 test
were performed on the voided urine sample that was provided before the cystoscopy.
In this study, we demonstrate that high-risk patients with negative cystoscopy on surveillance, but positive urine NMP22, have a higher rate of recurrence and reduced recurrence-free survival time in comparison to patients who have a negative NMP22 test
. In contrast, there was no evidence to suggest that urine cytology has the same predictive capability.
The NMP22 test
has a highly variable reported sensitivity and specificity.
The investigators compared the NMP22 test
results with cytology results, with cystoscopy as the reference standard.
In an interview, he said the NMP22 test
is ideal for general practitioners because they can pretty well rule out bladder cancer if it is negative.
False-positive results of the NMP22 test
due to hematuria.
The NMP22 Test
Kit is cleared for marketing in the United States for management and screening of individuals at risk of bladder cancer.
Several studies reported sensitivities for the NMP22 test
ranging from 68%  to l00%,  without significant differences.
The cut-off point for NMP22 test
was accepted as 10 U/mL.
The NMP22 test
(NMP22[R] Test Kit; Matritech, Inc.) is an enzyme immunoassay that detects the NMP complexes, specifically NMP22.
(Newton, MA; 617-928-0820), a company specializing in products designed to manage and screen cancer, announced that it has been issued United States Patent 5,882,876 by the United States Patent and Trademark Office for its invention using a nuclear matrix protein in Matritech's urine-based NMP22 Test
Kit for bladder cancer.